首页 > 最新文献

The American journal of the medical sciences最新文献

英文 中文
Identification and validation of leukemia inhibitory factor as a protective factor in ischemic acute kidney injury. 鉴定和验证白血病抑制因子作为缺血性急性肾损伤的保护因子。
Pub Date : 2024-09-21 DOI: 10.1016/j.amjms.2024.09.010
Lemei Hu, Chen Jiao, Haiyu Gu, Zhigang Zhu, Ming Liang

Background: Ischemia-reperfusion injury (IRI) is a common pathophysiological mechanism of acute kidney injury (AKI). There is an urgent need for a more comprehensive analysis of its underlying mechanisms.

Materials and methods: The RNA-sequencing dataset GSE153625 was used to examine differentially expressed genes (DEGs) of kidney tissues in IRI-AKI mice compared with sham mice. We used 10 algorithms provided by cytohubba plugin and four external datasets (GSE192532, GSE52004, GSE98622, and GSE185383) to screen for hub genes. The IRI-AKI mouse model with different reperfusion times was established to validate the expression of hub gene in the kidneys. HK-2 cells were cultured in vitro under hypoxia/reoxygenation (H/R) conditions, via transfection with si-LIF or supplementation with the LIF protein to explore the function of the LIF gene.

Results: We screened a total of 1,540 DEGs in the IRI group compared with the sham group and identified that the LIF hub gene may play potential roles in IRI-AKI. LIF was markedly upregulated in the kidney tissues of IRI-AKI mice, as well as in HK-2 cells grown under H/R conditions. The knockdown of LIF aggravated apoptosis and oxidative stress (OS) injury under H/R conditions. Administration of the LIF protein rescued the effects of si-LIF, alleviating cellular apoptosis and OS.

Conclusion: These findings indicate an important role of the LIF gene in term of regulating apoptosis and OS in the early phases of IRI-AKI. Targeting LIF may therefore represent a promising therapeutic strategy for IRI-AKI.

背景:缺血再灌注损伤(IRI)是急性肾损伤(AKI)的常见病理生理机制。目前迫切需要对其潜在机制进行更全面的分析:我们使用 RNA 序列数据集 GSE153625 研究了 IRI-AKI 小鼠与假小鼠肾脏组织的差异表达基因(DEGs)。我们使用 cytohubba 插件提供的 10 种算法和四个外部数据集(GSE192532、GSE52004、GSE98622 和 GSE185383)筛选枢纽基因。建立了不同再灌注时间的 IRI-AKI 小鼠模型,以验证枢纽基因在肾脏中的表达。在缺氧/再氧合(H/R)条件下体外培养HK-2细胞,通过转染si-LIF或补充LIF蛋白来探索LIF基因的功能:结果:与假手术组相比,我们在IRI组共筛选了1,540个DEGs,发现LIF中枢基因可能在IRI-AKI中发挥潜在作用。LIF在IRI-AKI小鼠的肾脏组织以及在H/R条件下生长的HK-2细胞中明显上调。敲除 LIF 会加重 H/R 条件下的细胞凋亡和氧化应激(OS)损伤。给予 LIF 蛋白可缓解 si-LIF 的影响,减轻细胞凋亡和氧化应激损伤:这些研究结果表明,在 IRI-AKI 的早期阶段,LIF 基因在调节细胞凋亡和 OS 方面起着重要作用。因此,以LIF为靶点可能是治疗IRI-AKI的一种有前景的策略。
{"title":"Identification and validation of leukemia inhibitory factor as a protective factor in ischemic acute kidney injury.","authors":"Lemei Hu, Chen Jiao, Haiyu Gu, Zhigang Zhu, Ming Liang","doi":"10.1016/j.amjms.2024.09.010","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.010","url":null,"abstract":"<p><strong>Background: </strong>Ischemia-reperfusion injury (IRI) is a common pathophysiological mechanism of acute kidney injury (AKI). There is an urgent need for a more comprehensive analysis of its underlying mechanisms.</p><p><strong>Materials and methods: </strong>The RNA-sequencing dataset GSE153625 was used to examine differentially expressed genes (DEGs) of kidney tissues in IRI-AKI mice compared with sham mice. We used 10 algorithms provided by cytohubba plugin and four external datasets (GSE192532, GSE52004, GSE98622, and GSE185383) to screen for hub genes. The IRI-AKI mouse model with different reperfusion times was established to validate the expression of hub gene in the kidneys. HK-2 cells were cultured in vitro under hypoxia/reoxygenation (H/R) conditions, via transfection with si-LIF or supplementation with the LIF protein to explore the function of the LIF gene.</p><p><strong>Results: </strong>We screened a total of 1,540 DEGs in the IRI group compared with the sham group and identified that the LIF hub gene may play potential roles in IRI-AKI. LIF was markedly upregulated in the kidney tissues of IRI-AKI mice, as well as in HK-2 cells grown under H/R conditions. The knockdown of LIF aggravated apoptosis and oxidative stress (OS) injury under H/R conditions. Administration of the LIF protein rescued the effects of si-LIF, alleviating cellular apoptosis and OS.</p><p><strong>Conclusion: </strong>These findings indicate an important role of the LIF gene in term of regulating apoptosis and OS in the early phases of IRI-AKI. Targeting LIF may therefore represent a promising therapeutic strategy for IRI-AKI.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miRNA-105-5p Regulates the Histone Deacetylase HDAC2 through FOXG1 to Affect the Malignant Biological Behavior of Triple-negative Breast Cancer Cells. miRNA-105-5p 通过 FOXG1 调控组蛋白去乙酰化酶 HDAC2 影响三阴性乳腺癌细胞的恶性生物学行为
Pub Date : 2024-09-21 DOI: 10.1016/j.amjms.2024.09.009
Li Wang, Zaoxiu Hu, Han Bai, Li Chang, Ceshi Chen, Wenhui Li

Background: Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer (BC). Some potential molecular targets have been identified, and miR-105-5p was found to be abnormally expressed in TNBC tissues.

Objective: The objective of this study was to probe the effect of miR-105-5p on TNBC via FOXG1/HDAC2-mediated acetylation.

Methods: An animal model of TNBC was established by injecting BC cells into the axillary area of nude mice. The levels of miR-105-5p, FOXG1, HDAC2, Bcl-2, Bax, and Ki67 were detected via RT‒qPCR, Western blotting and immunohistochemistry. Flow cytometry, CCK-8, Transwell and colony formation assays were used to measure apoptosis, proliferation and migration, respectively. Total histone acetylation levels were measured by ELISA. The binding of FOXG1 to HDAC2 was detected by co-immunoprecipitation. The binding relationship between miR-105-5p and FOXG1 was verified using a dual-luciferase reporter gene assay.

Results: In this study, miR-105-5p and HDAC2 were highly expressed in the MDA-MB-231 and BT-549 BC cell lines, whereas FOXG1 was expressed at low levels. The inhibition of miR-105-5p inhibited the proliferation and migration of MDA-MB-231 and BT-549 cells and promoted their apoptosis. Bioinformatics analysis revealed that miR-105-5p and FOXG1 had a negative targeting regulatory relationship. FOXG1 overexpression had a similar effect on cancer cells as the inhibition of miR-105-5p. Moreover, experiments revealed that FOXG1 and HDAC2 could bind to each other and that HDAC2 overexpression or treatment with the histone acetyltransferase inhibitor Garcinol weakened the effect of FOXG1 overexpression. In addition, FOXG1 knockdown inhibited the effect of the miR-105-5p inhibitor, while Garcinol treatment further enhanced the effect of FOXG1 knockdown, inhibited histone acetylation, promoted the proliferation and migration of cancer cells, and inhibited apoptosis. Moreover, the in vivo results confirmed the in vitro results.

Conclusion: miR-105-5p promotes HDAC2 expression by reducing FOXG1, inhibits histone acetylation, and aggravates the malignant biological behavior of TNBC cells.

背景:三阴性乳腺癌(TNBC三阴性乳腺癌(TNBC)是乳腺癌(BC)的一种特殊亚型。目前已发现一些潜在的分子靶点,并发现 miR-105-5p 在 TNBC 组织中异常表达:本研究旨在探讨 miR-105-5p 通过 FOXG1/HDAC2- 介导的乙酰化对 TNBC 的影响:方法:通过向裸鼠腋窝注射BC细胞,建立TNBC动物模型。通过 RT-qPCR、Western 印迹和免疫组化检测 miR-105-5p、FOXG1、HDAC2、Bcl-2、Bax 和 Ki67 的水平。流式细胞术、CCK-8、Transwell 和集落形成试验分别用于检测细胞凋亡、增殖和迁移。用酶联免疫吸附法测定组蛋白乙酰化总水平。共免疫沉淀法检测了 FOXG1 与 HDAC2 的结合。使用双荧光素酶报告基因检测法验证了 miR-105-5p 与 FOXG1 的结合关系:结果:在这项研究中,miR-105-5p 和 HDAC2 在 MDA-MB-231 和 BT-549 BC 细胞系中高表达,而 FOXG1 则低表达。抑制miR-105-5p可抑制MDA-MB-231和BT-549细胞的增殖和迁移,并促进其凋亡。生物信息学分析表明,miR-105-5p 与 FOXG1 存在负靶向调控关系。FOXG1 过表达对癌细胞的影响与抑制 miR-105-5p 相似。此外,实验发现 FOXG1 和 HDAC2 可以相互结合,HDAC2 过表达或用组蛋白乙酰转移酶抑制剂加西诺处理会削弱 FOXG1 过表达的效果。此外,FOXG1敲除抑制了miR-105-5p抑制剂的作用,而Garcinol处理则进一步增强了FOXG1敲除的作用,抑制了组蛋白乙酰化,促进了癌细胞的增殖和迁移,并抑制了细胞凋亡。结论:miR-105-5p 通过降低 FOXG1 促进 HDAC2 的表达,抑制组蛋白乙酰化,加重 TNBC 细胞的恶性生物学行为。
{"title":"miRNA-105-5p Regulates the Histone Deacetylase HDAC2 through FOXG1 to Affect the Malignant Biological Behavior of Triple-negative Breast Cancer Cells.","authors":"Li Wang, Zaoxiu Hu, Han Bai, Li Chang, Ceshi Chen, Wenhui Li","doi":"10.1016/j.amjms.2024.09.009","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.009","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer (BC). Some potential molecular targets have been identified, and miR-105-5p was found to be abnormally expressed in TNBC tissues.</p><p><strong>Objective: </strong>The objective of this study was to probe the effect of miR-105-5p on TNBC via FOXG1/HDAC2-mediated acetylation.</p><p><strong>Methods: </strong>An animal model of TNBC was established by injecting BC cells into the axillary area of nude mice. The levels of miR-105-5p, FOXG1, HDAC2, Bcl-2, Bax, and Ki67 were detected via RT‒qPCR, Western blotting and immunohistochemistry. Flow cytometry, CCK-8, Transwell and colony formation assays were used to measure apoptosis, proliferation and migration, respectively. Total histone acetylation levels were measured by ELISA. The binding of FOXG1 to HDAC2 was detected by co-immunoprecipitation. The binding relationship between miR-105-5p and FOXG1 was verified using a dual-luciferase reporter gene assay.</p><p><strong>Results: </strong>In this study, miR-105-5p and HDAC2 were highly expressed in the MDA-MB-231 and BT-549 BC cell lines, whereas FOXG1 was expressed at low levels. The inhibition of miR-105-5p inhibited the proliferation and migration of MDA-MB-231 and BT-549 cells and promoted their apoptosis. Bioinformatics analysis revealed that miR-105-5p and FOXG1 had a negative targeting regulatory relationship. FOXG1 overexpression had a similar effect on cancer cells as the inhibition of miR-105-5p. Moreover, experiments revealed that FOXG1 and HDAC2 could bind to each other and that HDAC2 overexpression or treatment with the histone acetyltransferase inhibitor Garcinol weakened the effect of FOXG1 overexpression. In addition, FOXG1 knockdown inhibited the effect of the miR-105-5p inhibitor, while Garcinol treatment further enhanced the effect of FOXG1 knockdown, inhibited histone acetylation, promoted the proliferation and migration of cancer cells, and inhibited apoptosis. Moreover, the in vivo results confirmed the in vitro results.</p><p><strong>Conclusion: </strong>miR-105-5p promotes HDAC2 expression by reducing FOXG1, inhibits histone acetylation, and aggravates the malignant biological behavior of TNBC cells.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lung Transplant Access Disparities for Asian Patients with Idiopathic Pulmonary Fibrosis. 亚裔特发性肺纤维化患者接受肺移植的机会不均等。
Pub Date : 2024-09-18 DOI: 10.1016/j.amjms.2024.09.006
Aaron Pathak, Shreyas Sinha, Neeraj Sinha
{"title":"Lung Transplant Access Disparities for Asian Patients with Idiopathic Pulmonary Fibrosis.","authors":"Aaron Pathak, Shreyas Sinha, Neeraj Sinha","doi":"10.1016/j.amjms.2024.09.006","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.006","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uncontrolled Anger: A Fuel for Cardiovascular Disease? 无法控制的愤怒:心血管疾病的燃料?
Pub Date : 2024-09-17 DOI: 10.1016/j.amjms.2024.09.005
Eeshal Fatima, Um E Habibah, Zain Ali Nadeem
{"title":"Uncontrolled Anger: A Fuel for Cardiovascular Disease?","authors":"Eeshal Fatima, Um E Habibah, Zain Ali Nadeem","doi":"10.1016/j.amjms.2024.09.005","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.005","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pleural Complications in Patients with Renal Cell Carcinoma Undergoing Percutaneous Cryoablation: A Retrospective Analysis of its Incidence and Risk Factors. 接受经皮冷冻消融术的肾细胞癌患者的胸膜并发症:对其发生率和风险因素的回顾性分析。
Pub Date : 2024-09-16 DOI: 10.1016/j.amjms.2024.09.003
Ibrahim Khatim, Isam Albaba, Marc A Judson, Kurt Hu, Sana Ali, Harpreet Singh, Khezar Syed, Moses Koo, Timothy Yung, Paul Feustel, Ramkrishna Patel, Gary Siskin, Amit Chopra

Rationale: Observations from our clinical practice indicate a notable occurrence of pleural complications post-percutaneous renal cryoablation (PRC).

Objective: To identify the incidence of pleural complications following PRC and potential risk factors associated with post-procedural pleural complications.

Materials and methods: This was a retrospective cohort analysis of patients undergoing PRC at two tertiary hospital systems between 2016 and 2022. Patient characteristics, radiological and clinical data, and procedure techniques were collected in a database to identify potential risk factors.

Results: A total of 285 patients were identified who underwent 312 PRC procedures during the specified inclusion period. Among these, 10 procedures (3.2%) led to pleural complications, all manifesting as pleural effusions. Of these complications, 3 patients (1%) required pleural drainage. Factors associated with an increased risk of pleural complications included a larger mean tumor size (4.3 cm vs 2.7 cm, P = <0.001), cryoprobe applicator entry at the T10-T11 level as opposed to lower sites (P = 0.029), and a higher median number of cryoprobe applicators employed (3.5 vs 2.0, P = 0.001). Moreover, individuals who experienced pleural complications had a longer median hospital stay (4.0 vs 0, P≤0.001) and a higher rate of blood transfusions (40% vs 0.7%, P≤0.001).

Conclusion: Pleural complications from percutaneous renal cryoablation are rare. To further reduce the risk, higher insertion points (above T12) and utilizing more than two cryoprobe applicators should be avoided when feasible. Pleural complications in patients with new respiratory symptoms after PRC should be considered.

理论依据:我们的临床实践观察表明,经皮肾冷冻消融术(PRC)后胸膜并发症的发生率很高:目的:确定经皮肾脏冷冻消融术后胸膜并发症的发生率以及与术后胸膜并发症相关的潜在风险因素:这是一项回顾性队列分析,研究对象是2016年至2022年期间在两家三级医院系统接受PRC治疗的患者。在数据库中收集了患者特征、放射学和临床数据以及手术技术,以确定潜在的风险因素:在规定的纳入期内,共有285名患者接受了312例PRC手术。其中,10 例手术(3.2%)导致胸膜并发症,均表现为胸腔积液。在这些并发症中,3 名患者(1%)需要进行胸腔引流。胸膜并发症风险增加的相关因素包括肿瘤平均大小较大(4.3 厘米 vs 2.7 厘米,P = 结论:肿瘤平均大小越大,胸膜并发症风险越高:经皮肾冷冻消融术引起胸膜并发症的情况很少见。为进一步降低风险,在可行的情况下,应避免较高的插入点(T12 以上)和使用两个以上的冷冻探针。经皮肾冷冻消融术后出现新呼吸道症状的患者应考虑胸膜并发症。
{"title":"Pleural Complications in Patients with Renal Cell Carcinoma Undergoing Percutaneous Cryoablation: A Retrospective Analysis of its Incidence and Risk Factors.","authors":"Ibrahim Khatim, Isam Albaba, Marc A Judson, Kurt Hu, Sana Ali, Harpreet Singh, Khezar Syed, Moses Koo, Timothy Yung, Paul Feustel, Ramkrishna Patel, Gary Siskin, Amit Chopra","doi":"10.1016/j.amjms.2024.09.003","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.003","url":null,"abstract":"<p><strong>Rationale: </strong>Observations from our clinical practice indicate a notable occurrence of pleural complications post-percutaneous renal cryoablation (PRC).</p><p><strong>Objective: </strong>To identify the incidence of pleural complications following PRC and potential risk factors associated with post-procedural pleural complications.</p><p><strong>Materials and methods: </strong>This was a retrospective cohort analysis of patients undergoing PRC at two tertiary hospital systems between 2016 and 2022. Patient characteristics, radiological and clinical data, and procedure techniques were collected in a database to identify potential risk factors.</p><p><strong>Results: </strong>A total of 285 patients were identified who underwent 312 PRC procedures during the specified inclusion period. Among these, 10 procedures (3.2%) led to pleural complications, all manifesting as pleural effusions. Of these complications, 3 patients (1%) required pleural drainage. Factors associated with an increased risk of pleural complications included a larger mean tumor size (4.3 cm vs 2.7 cm, P = <0.001), cryoprobe applicator entry at the T10-T11 level as opposed to lower sites (P = 0.029), and a higher median number of cryoprobe applicators employed (3.5 vs 2.0, P = 0.001). Moreover, individuals who experienced pleural complications had a longer median hospital stay (4.0 vs 0, P≤0.001) and a higher rate of blood transfusions (40% vs 0.7%, P≤0.001).</p><p><strong>Conclusion: </strong>Pleural complications from percutaneous renal cryoablation are rare. To further reduce the risk, higher insertion points (above T12) and utilizing more than two cryoprobe applicators should be avoided when feasible. Pleural complications in patients with new respiratory symptoms after PRC should be considered.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hsa_circ_0087784 enhance snon-small cell lung cancer progression via the miR-576-5p/CDCA4 axis. Hsa_circ_0087784 通过 miR-576-5p/CDCA4 轴增强小细胞肺癌的进展。
Pub Date : 2024-09-13 DOI: 10.1016/j.amjms.2024.09.002
Bin Shang, Long Li, Gang Wang, Gang Liu, Xiaosong Yang, Jian Gao, Weiwei Yin

Background: Circular RNAs (circRNAs) belong to a family of covalently closed single-stranded RNAs that have been implicated in cancer progression. Previous studies have reported that hsa_circ_0087784 was abnormally expressed in breast cancer. However, the role of hsa_circ_0087784 in non-small cell lung cancer (NSCLC) is unknown.

Methods: Here, we used RT-qPCR and FISH to examine hsa_circ_0087784 expression in NSCLC cells and tissue samples. The dual-luciferase reporter assay was used to identify downstream targets of hsa_circ_0087784. Transwell migration, 5-ethynyl-2´-deoxyuridine, and CCK-8 assays were used to examine migration and proliferation. Tumorigenesis and metastasis assays were used to determine the role of hsa_circ_0087784 in NSCLC progression in a mouse tumor xenograft model in vivo.

Results: We found that hsa_circ_0087784 was expressed at significantly high levels in NSCLC tissue samples and cell lines. Downregulation of hsa_circ_0087784 suppressed NSCLC cellular proliferation, as well as migration. Our dual-luciferase reporter assay revealed that miR-576-5p and CDCA4 were downstream targets of hsa_circ_0087784. CDCA4 overexpression or miR-576-5p suppression reversed the effects of hsa_circ_0087784 silencing on NSCLC cell migration, and EMT-related protein expression levels.

Conclusion: Our findings suggested that downregulation of hsa_circ_0087784 inhibited NSCLC metastasis and progression through the regulation of CDCA4 expression and miR-576-5psponging.

背景:环状 RNA(circRNA)属于共价封闭的单链 RNA 家族,与癌症进展有关联。以前的研究曾报道 hsa_circ_0087784 在乳腺癌中异常表达。方法:我们使用 RT-qPCR 和 FISH 检测了 hsa_circ_0087784 在 NSCLC 细胞和组织样本中的表达。方法:我们采用 RT-qPCR 和 FISH 方法检测了 hsa_circ_0087784 在 NSCLC 细胞和组织样本中的表达,并使用双荧光素酶报告实验确定了 hsa_circ_0087784 的下游靶标。Transwell迁移、5-乙炔基-2´-脱氧尿苷和CCK-8试验用于检测迁移和增殖。肿瘤发生和转移试验用于确定 hsa_circ_0087784 在小鼠体内肿瘤异种移植模型中对 NSCLC 进展的作用:结果:我们发现,hsa_circ_0087784在NSCLC组织样本和细胞系中的表达水平很高。下调 hsa_circ_0087784 可抑制 NSCLC 细胞的增殖和迁移。我们的双荧光素酶报告实验发现,miR-576-5p 和 CDCA4 是 hsa_circ_0087784 的下游靶标。CDCA4 的过表达或 miR-576-5p 的抑制逆转了 hsa_circ_0087784 沉默对 NSCLC 细胞迁移和 EMT 相关蛋白表达水平的影响:我们的研究结果表明,下调hsa_circ_0087784可通过调控CDCA4的表达和miR-576-5psonging抑制NSCLC的转移和进展。
{"title":"Hsa_circ_0087784 enhance snon-small cell lung cancer progression via the miR-576-5p/CDCA4 axis.","authors":"Bin Shang, Long Li, Gang Wang, Gang Liu, Xiaosong Yang, Jian Gao, Weiwei Yin","doi":"10.1016/j.amjms.2024.09.002","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.002","url":null,"abstract":"<p><strong>Background: </strong>Circular RNAs (circRNAs) belong to a family of covalently closed single-stranded RNAs that have been implicated in cancer progression. Previous studies have reported that hsa_circ_0087784 was abnormally expressed in breast cancer. However, the role of hsa_circ_0087784 in non-small cell lung cancer (NSCLC) is unknown.</p><p><strong>Methods: </strong>Here, we used RT-qPCR and FISH to examine hsa_circ_0087784 expression in NSCLC cells and tissue samples. The dual-luciferase reporter assay was used to identify downstream targets of hsa_circ_0087784. Transwell migration, 5-ethynyl-2´-deoxyuridine, and CCK-8 assays were used to examine migration and proliferation. Tumorigenesis and metastasis assays were used to determine the role of hsa_circ_0087784 in NSCLC progression in a mouse tumor xenograft model in vivo.</p><p><strong>Results: </strong>We found that hsa_circ_0087784 was expressed at significantly high levels in NSCLC tissue samples and cell lines. Downregulation of hsa_circ_0087784 suppressed NSCLC cellular proliferation, as well as migration. Our dual-luciferase reporter assay revealed that miR-576-5p and CDCA4 were downstream targets of hsa_circ_0087784. CDCA4 overexpression or miR-576-5p suppression reversed the effects of hsa_circ_0087784 silencing on NSCLC cell migration, and EMT-related protein expression levels.</p><p><strong>Conclusion: </strong>Our findings suggested that downregulation of hsa_circ_0087784 inhibited NSCLC metastasis and progression through the regulation of CDCA4 expression and miR-576-5psponging.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low Prevalence of Peptic Ulcer Disease in Hospitalized Patients with Cystic Fibrosis: a national database study. 囊性纤维化住院患者消化性溃疡发病率低:一项国家数据库研究。
Pub Date : 2024-09-06 DOI: 10.1016/j.amjms.2024.09.001
Maya Mahmoud, Eugene Nwankwo, Zidong Zhang, Neel Matiwala, Rohan Tripathi, Islam Mohamed, Christopher Barrios, Wing-Kin Syn, Christine Hachem

Background: Although cystic fibrosis (CF) is widely considered a lung disease, the prevalence of CF-specific gastrointestinal symptoms and diseases has continued to rise. Peptic ulcer disease (PUD) has not been well-studied among people with CF (PwCF) and may be a common cause of abdominal symptoms. In PwCF, impaired bicarbonate secretion and unbuffered gastric acid production have been attributed to the development of ulcers, although ulcers remain uncommon. The objective of this study was to evaluate the prevalence of PUD in PwCF and assess for possible contributing factors.

Methods: This study utilized the National Inpatient Sample (NIS) database. All patients 18 years or older with CF were identified from 2014 to 2019. Relevant patient characteristics and procedures were identified using ICD-9 and ICD-10 codes. Linear trend, bivariate analyses, and multiple regression analysis were performed. The outcomes of interest were peptic ulcer disease, pancreatic insufficiency, and nonalcoholic steatohepatitis or NASH. All analyses accounted for complex sampling scheme of the NIS.

Results: The total prevalence of PwCF in the National Inpatient Sample (NIS) database was 0.08%, and the number was stable year to year from 2014 to 2019. Hispanic patients were more likely to be diagnosed with PUD than other white (aOR 1.802 [1.311,2.476]). Multiple regression analysis indicated that PUD in PwCF was strongly associated with a diagnosis of NASH (aOR 2.421[1.197, 4.898]). PUD patients were less likely to have pancreatic insufficiency compared to the non-PUD group (aOR 0.583 [0.455, 0.745]).

Conclusion: Although cystic fibrosis has been historically known as a disease of childhood, advancements in therapy have led to prolonged life expectancy and higher prevalence for cystic fibrosis-related digestive diseases. This study revealed a low prevalence of PUD in PwCF. Hispanics and those with NASH are more likely to develop peptic ulcers.

背景:尽管囊性纤维化(CF)被普遍认为是一种肺部疾病,但CF特有的胃肠道症状和疾病的发病率却在持续上升。消化性溃疡病(PUD)在囊性纤维化患者(PwCF)中尚未得到充分研究,但可能是导致腹部症状的常见原因。在 PwCF 患者中,碳酸氢盐分泌受损和胃酸分泌不足是导致溃疡发生的原因,但溃疡仍不常见。本研究旨在评估 PwCF 中 PUD 的患病率,并评估可能的诱因:本研究利用了全国住院病人抽样(NIS)数据库。2014年至2019年期间,所有18岁或18岁以上的CF患者均被确定。使用 ICD-9 和 ICD-10 编码确定了相关的患者特征和手术。进行了线性趋势分析、双变量分析和多元回归分析。相关结果为消化性溃疡病、胰腺功能不全和非酒精性脂肪性肝炎或 NASH。所有分析均考虑了国家健康调查的复杂抽样方案:全国住院病人抽样(NIS)数据库中PwCF的总患病率为0.08%,从2014年到2019年,这一数字逐年稳定。西班牙裔患者比其他白人更有可能被诊断为PUD(aOR 1.802 [1.311,2.476] )。多元回归分析表明,PwCF 中的 PUD 与 NASH 诊断密切相关(aOR 2.421[1.197, 4.898])。与非 PUD 组相比,PUD 患者出现胰腺功能不全的可能性较低(aOR 0.583 [0.455, 0.745]):尽管囊性纤维化历来被认为是一种儿童疾病,但治疗的进步延长了患者的预期寿命,并提高了囊性纤维化相关消化系统疾病的患病率。这项研究显示,囊性纤维化患者中 PUD 的发病率较低。西班牙裔和患有 NASH 的人更容易患消化性溃疡。
{"title":"Low Prevalence of Peptic Ulcer Disease in Hospitalized Patients with Cystic Fibrosis: a national database study.","authors":"Maya Mahmoud, Eugene Nwankwo, Zidong Zhang, Neel Matiwala, Rohan Tripathi, Islam Mohamed, Christopher Barrios, Wing-Kin Syn, Christine Hachem","doi":"10.1016/j.amjms.2024.09.001","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.09.001","url":null,"abstract":"<p><strong>Background: </strong>Although cystic fibrosis (CF) is widely considered a lung disease, the prevalence of CF-specific gastrointestinal symptoms and diseases has continued to rise. Peptic ulcer disease (PUD) has not been well-studied among people with CF (PwCF) and may be a common cause of abdominal symptoms. In PwCF, impaired bicarbonate secretion and unbuffered gastric acid production have been attributed to the development of ulcers, although ulcers remain uncommon. The objective of this study was to evaluate the prevalence of PUD in PwCF and assess for possible contributing factors.</p><p><strong>Methods: </strong>This study utilized the National Inpatient Sample (NIS) database. All patients 18 years or older with CF were identified from 2014 to 2019. Relevant patient characteristics and procedures were identified using ICD-9 and ICD-10 codes. Linear trend, bivariate analyses, and multiple regression analysis were performed. The outcomes of interest were peptic ulcer disease, pancreatic insufficiency, and nonalcoholic steatohepatitis or NASH. All analyses accounted for complex sampling scheme of the NIS.</p><p><strong>Results: </strong>The total prevalence of PwCF in the National Inpatient Sample (NIS) database was 0.08%, and the number was stable year to year from 2014 to 2019. Hispanic patients were more likely to be diagnosed with PUD than other white (aOR 1.802 [1.311,2.476]). Multiple regression analysis indicated that PUD in PwCF was strongly associated with a diagnosis of NASH (aOR 2.421[1.197, 4.898]). PUD patients were less likely to have pancreatic insufficiency compared to the non-PUD group (aOR 0.583 [0.455, 0.745]).</p><p><strong>Conclusion: </strong>Although cystic fibrosis has been historically known as a disease of childhood, advancements in therapy have led to prolonged life expectancy and higher prevalence for cystic fibrosis-related digestive diseases. This study revealed a low prevalence of PUD in PwCF. Hispanics and those with NASH are more likely to develop peptic ulcers.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of 24 vs 72-hour octreotide infusion in acute esophageal variceal hemorrhage - a multi-center, randomized clinical trial. 在急性食管静脉曲张出血中输注 24 小时与 72 小时奥曲肽的比较--一项多中心随机临床试验。
Pub Date : 2024-09-04 DOI: 10.1016/j.amjms.2024.08.027
Jad Allam, Silvio De Melo, Linda A Feagins, Deepak Agrawal, Miguel Malespin, Asim Shuja, Luis F Lara, Don C Rockey

Background: Current guidelines lack clarity about the optimal duration of octreotide therapy for patients with esophageal variceal hemorrhage (EVH). To address this lack of evidence, we conducted a randomized clinical trial (RCT) of 24-hours versus 72-hours continuous infusion of octreotide for patients with EVH.

Methods: This multi-center, prospective RCT (NCT03624517), randomized patients with EVH to 24-hour versus 72-hour infusion of octreotide. Patients were required to undergo esophageal variceal band ligation prior to enrollment. The primary endpoint was rebleeding rate at 72 hours. The study was terminated early due to an inability to recruit during and after the COVID-19 epidemic.

Results: For patients randomized to 72-hours (n = 19) of octreotide vs 24-hours (n = 15), there were no differences in the need for transfusion, average pRBC units transfused per patient (3 units vs 2 units), infection (5% vs 0%), mechanical ventilation (11% vs 7%), or the need for vasopressors (5% vs 3%), respectively (none of these differences were statistically significantly different). There were 2 re-bleeding events in the 72-hour group (11%), and no re-bleeding events in the 24-hour group (p = 0.49). 8/15 of patients receiving 24 hours of octreotide were discharged at or before hospital day 3 while none in the 72-hour group was discharged before day 3 (p < 0.001). There was one death (in the 72-hour group) within 30 days.

Conclusions: A 24-hour infusion is non-inferior to a 72-hour infusion of octreotide for prevention of re-bleeding in patients with EVH. We propose that shortened octreotide duration may help reduce hospital stay and related costs in these patients.

背景:目前的指南没有明确食管静脉曲张出血(EVH)患者接受奥曲肽治疗的最佳时间。为了解决证据不足的问题,我们开展了一项随机临床试验(RCT),对食管静脉曲张出血患者连续输注奥曲肽 24 小时与 72 小时进行对比:这项多中心前瞻性 RCT(NCT03624517)将 EVH 患者随机分为 24 小时输注奥曲肽和 72 小时输注奥曲肽两种。患者必须在入组前接受食管静脉曲张带结扎手术。主要终点是72小时后的再出血率。由于在 COVID-19 流行期间和之后无法招募到患者,研究提前终止:随机接受 72 小时奥曲肽治疗(19 人)与 24 小时奥曲肽治疗(15 人)的患者在输血需求、每位患者平均输注 pRBC 单位(3 单位 vs 2 单位)、感染(5% vs 0%)、机械通气(11% vs 7%)或血管加压药需求(5% vs 3%)方面分别没有差异(这些差异在统计学上都没有显著性差异)。72 小时组有 2 例再出血事件(11%),24 小时组无再出血事件(P = 0.49)。在接受 24 小时奥曲肽治疗的患者中,8/15 的患者在住院第 3 天或之前出院,而在 72 小时组中,没有患者在住院第 3 天之前出院(p < 0.001)。有一名患者(72小时组)在30天内死亡:结论:在预防EVH患者再出血方面,24小时输注奥曲肽并不比72小时输注奥曲肽效果差。我们认为缩短奥曲肽的输注时间有助于减少这些患者的住院时间和相关费用。
{"title":"Comparison of 24 vs 72-hour octreotide infusion in acute esophageal variceal hemorrhage - a multi-center, randomized clinical trial.","authors":"Jad Allam, Silvio De Melo, Linda A Feagins, Deepak Agrawal, Miguel Malespin, Asim Shuja, Luis F Lara, Don C Rockey","doi":"10.1016/j.amjms.2024.08.027","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.027","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines lack clarity about the optimal duration of octreotide therapy for patients with esophageal variceal hemorrhage (EVH). To address this lack of evidence, we conducted a randomized clinical trial (RCT) of 24-hours versus 72-hours continuous infusion of octreotide for patients with EVH.</p><p><strong>Methods: </strong>This multi-center, prospective RCT (NCT03624517), randomized patients with EVH to 24-hour versus 72-hour infusion of octreotide. Patients were required to undergo esophageal variceal band ligation prior to enrollment. The primary endpoint was rebleeding rate at 72 hours. The study was terminated early due to an inability to recruit during and after the COVID-19 epidemic.</p><p><strong>Results: </strong>For patients randomized to 72-hours (n = 19) of octreotide vs 24-hours (n = 15), there were no differences in the need for transfusion, average pRBC units transfused per patient (3 units vs 2 units), infection (5% vs 0%), mechanical ventilation (11% vs 7%), or the need for vasopressors (5% vs 3%), respectively (none of these differences were statistically significantly different). There were 2 re-bleeding events in the 72-hour group (11%), and no re-bleeding events in the 24-hour group (p = 0.49). 8/15 of patients receiving 24 hours of octreotide were discharged at or before hospital day 3 while none in the 72-hour group was discharged before day 3 (p < 0.001). There was one death (in the 72-hour group) within 30 days.</p><p><strong>Conclusions: </strong>A 24-hour infusion is non-inferior to a 72-hour infusion of octreotide for prevention of re-bleeding in patients with EVH. We propose that shortened octreotide duration may help reduce hospital stay and related costs in these patients.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blocking of SIRT7/FOXO3a Axis by miR-152-3p Enhances Cisplatin Sensitivity in Breast Cancer. miR-152-3p 阻断 SIRT7/FOXO3a 轴可提高乳腺癌患者对顺铂的敏感性
Pub Date : 2024-09-04 DOI: 10.1016/j.amjms.2024.08.028
Xiangkui Shi, Yunfei Ji, Xueqing Wu, Yu Du, Xiaonan Yan, Yan Wang, Xiaobing Xia

Background: Cisplatin-based chemoresistance is major obstacle for breast cancer (BC) including Triple-negative breast cancer (TNBC). SIRT7 is reportedly involved in the progression of BC, the underlining mechanism in Cisplatin-based chemoresistance in BC remains unclear. This work is to elucidate effects of SIRT7 on cisplatin resistance in breast cancer regulated by miR-152-3p.

Methods: The RNA expression of SIRT7 and miRNAs in breast cancer were available from TCGA database. SIRT7-targeted miRNAs were predicted by TargetScan, miRanda, miRDB databases. The association of SIRT7 expression with predicted miRNA was validated by Luciferase assay. Cell apoptosis was determined by Flow cytometry. Cell viability was detected by CCK8 assay. The mRNA expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR) assay. Protein expression was determined by Western blotting assay.

Results: SIRT7 mRNA levels were dramatically enhanced in BC tissues compared to para-carcinoma tissues, also increased in BC patients with Cisplatin-based chemotherapy containing TNBC compared with those without. The increase of SIRT7 expression was obviously relevant to shorter survive time of them. Importantly, SIRT7 inhibition facilitated Cisplatin-induced cell apoptosis of TNBC (MDA-MB-231 and MDA-MB-468) and non- TNBC (MCF-7). Notably, miR-152-3p was predicted as a negative regulator of SIRT7 by overlapping downregulated miRNAs in BC patients treated with Cisplatin-based chemotherapy and miRNAs to target SIRT7. Mechanically, miR-152-3p blocked SIRT7 to stimulate an activation of FOXO3a, cleaved PARP1 and Caspase-3, sensitizing Cisplatin-induced apoptosis of BC cells.

Conclusions: Inhibition of SIRT7 by miR-152-3p may be a promising strategy against the resistance to cisplatin-based chemotherapy in BC containing TNBC.

背景:顺铂化疗耐药是乳腺癌(BC)(包括三阴性乳腺癌(TNBC))的主要障碍。据报道,SIRT7参与了乳腺癌的进展,但其对顺铂类药物的化疗耐药性的基本机制仍不清楚。本研究旨在阐明 miR-152-3p 调控的 SIRT7 对乳腺癌顺铂耐药的影响:方法:SIRT7和miRNA在乳腺癌中的RNA表达来自TCGA数据库。SIRT7靶向的miRNAs由TargetScan、miRanda和miRDB数据库预测。通过荧光素酶试验验证了 SIRT7 表达与预测 miRNA 的关联。细胞凋亡由流式细胞仪测定。用 CCK8 检测法检测细胞活力。实时定量聚合酶链反应(qRT-PCR)测定 mRNA 表达。蛋白表达通过 Western 印迹法测定:结果:与癌旁组织相比,SIRT7 mRNA水平在BC组织中显著升高;与未接受顺铂化疗的TNBC患者相比,SIRT7 mRNA水平在接受顺铂化疗的BC患者中也有所升高。SIRT7表达的增加显然与他们存活时间的缩短有关。重要的是,抑制SIRT7可促进顺铂诱导的TNBC(MDA-MB-231和MDA-MB-468)和非TNBC(MCF-7)细胞凋亡。值得注意的是,在接受以顺铂为基础的化疗的 BC 患者中,miR-152-3p 被预测为 SIRT7 的负调控因子,因为在这些患者中,下调的 miRNA 与靶向 SIRT7 的 miRNA 重叠。从机制上讲,miR-152-3p阻断了SIRT7,从而刺激了FOXO3a、PARP1和Caspase-3的裂解,使顺铂诱导的BC细胞凋亡敏感化:结论:miR-152-3p抑制SIRT7可能是一种很有前景的策略,可用于抑制BC(含TNBC)对顺铂化疗的耐药性。
{"title":"Blocking of SIRT7/FOXO3a Axis by miR-152-3p Enhances Cisplatin Sensitivity in Breast Cancer.","authors":"Xiangkui Shi, Yunfei Ji, Xueqing Wu, Yu Du, Xiaonan Yan, Yan Wang, Xiaobing Xia","doi":"10.1016/j.amjms.2024.08.028","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.028","url":null,"abstract":"<p><strong>Background: </strong>Cisplatin-based chemoresistance is major obstacle for breast cancer (BC) including Triple-negative breast cancer (TNBC). SIRT7 is reportedly involved in the progression of BC, the underlining mechanism in Cisplatin-based chemoresistance in BC remains unclear. This work is to elucidate effects of SIRT7 on cisplatin resistance in breast cancer regulated by miR-152-3p.</p><p><strong>Methods: </strong>The RNA expression of SIRT7 and miRNAs in breast cancer were available from TCGA database. SIRT7-targeted miRNAs were predicted by TargetScan, miRanda, miRDB databases. The association of SIRT7 expression with predicted miRNA was validated by Luciferase assay. Cell apoptosis was determined by Flow cytometry. Cell viability was detected by CCK8 assay. The mRNA expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR) assay. Protein expression was determined by Western blotting assay.</p><p><strong>Results: </strong>SIRT7 mRNA levels were dramatically enhanced in BC tissues compared to para-carcinoma tissues, also increased in BC patients with Cisplatin-based chemotherapy containing TNBC compared with those without. The increase of SIRT7 expression was obviously relevant to shorter survive time of them. Importantly, SIRT7 inhibition facilitated Cisplatin-induced cell apoptosis of TNBC (MDA-MB-231 and MDA-MB-468) and non- TNBC (MCF-7). Notably, miR-152-3p was predicted as a negative regulator of SIRT7 by overlapping downregulated miRNAs in BC patients treated with Cisplatin-based chemotherapy and miRNAs to target SIRT7. Mechanically, miR-152-3p blocked SIRT7 to stimulate an activation of FOXO3a, cleaved PARP1 and Caspase-3, sensitizing Cisplatin-induced apoptosis of BC cells.</p><p><strong>Conclusions: </strong>Inhibition of SIRT7 by miR-152-3p may be a promising strategy against the resistance to cisplatin-based chemotherapy in BC containing TNBC.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pressed for Understanding: Interstitial lung disease in Dry-Cleaning Workers. 亟待了解:干洗工人的间质性肺病。
Pub Date : 2024-09-03 DOI: 10.1016/j.amjms.2024.08.026
Ross Summer, Phoebe Chun

Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation and fibrosis of the pulmonary interstitium. Risk factors for ILD include various environmental exposures and identifying specific exposures offers a point of intervention for preventing disease. Here, we present several cases of patients who worked in the dry-cleaning business and have ILD or abnormalities consistent with early ILD on chest CT imaging. While this report does not attempt to establish causality, we hypothesize that exposure to the industrial solvent tetrachloroethylene may serve as a contributing factor given its links to epithelial injury, inflammation, redox imbalance and apoptosis. We hope that this report serves to not only inform readers of this possible connection between dry cleaning and ILD but also lay the foundation for additional studies examining the effects of tetrachloroethylene on the lung.

间质性肺病(ILD)是一组以肺间质炎症和纤维化为特征的异质性疾病。间质性肺病的危险因素包括各种环境暴露,识别特定的环境暴露为预防疾病提供了干预点。在此,我们介绍了几例曾在干洗行业工作并患有 ILD 或胸部 CT 成像出现与早期 ILD 一致的异常的患者。虽然本报告并不试图确定因果关系,但我们假设,接触工业溶剂四氯乙烯可能是一个诱因,因为它与上皮损伤、炎症、氧化还原失衡和细胞凋亡有关。我们希望本报告不仅能让读者了解干洗与 ILD 之间可能存在的联系,还能为更多有关四氯乙烯对肺部影响的研究奠定基础。
{"title":"Pressed for Understanding: Interstitial lung disease in Dry-Cleaning Workers.","authors":"Ross Summer, Phoebe Chun","doi":"10.1016/j.amjms.2024.08.026","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.08.026","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) represents a heterogeneous group of disorders characterized by inflammation and fibrosis of the pulmonary interstitium. Risk factors for ILD include various environmental exposures and identifying specific exposures offers a point of intervention for preventing disease. Here, we present several cases of patients who worked in the dry-cleaning business and have ILD or abnormalities consistent with early ILD on chest CT imaging. While this report does not attempt to establish causality, we hypothesize that exposure to the industrial solvent tetrachloroethylene may serve as a contributing factor given its links to epithelial injury, inflammation, redox imbalance and apoptosis. We hope that this report serves to not only inform readers of this possible connection between dry cleaning and ILD but also lay the foundation for additional studies examining the effects of tetrachloroethylene on the lung.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142142258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The American journal of the medical sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1